News for 2009

FDA says it finds no Vytorin-cancer link, but unsure

fda logo 100x100The U.S. Food and Drug Administration announced today that it found no clear link between ’s blockbuster drug Vytorin and increased risk of cancer, but it could not rule out the possibility that such a link exists. The agency reviewed data from three trials, including the controversial SEAS trial results, which had withheld from the public for 18 months as it aggressively marketed the drug.

Read the rest of this entry »

New study shows vytorin and zetia less effective than niacin

niacin2 100x100Vytorin has struck out again, this time in a clinical trial that compared the drug’s safety and efficacy to a prescription form of the B vitamin niacin. The results of the trial, which the New England Journal of Medicine featured in an article and two editorials, were presented Sunday at an American Heart Association meeting and showed that in a direct comparison, niacin worked significantly better than and in reducing arterial blockages. According to a report in NPR, “This study is the third to question whether ezetimibe drugs do what they’re supposed to.”

Read the rest of this entry »

Merck and Schering pay $41.5 million to settle NJ lawsuits

vytorin2 100x100 and , the pharmaceutical giants whose joint venture produced the blockbuster drug Vytorin, agreed to pay $41.5 million to settle 140-plus New Jersey lawsuits lodged against the manufacturers for misleading and improper marketing of the drug and for withholding the results of a clinical trial that showed to be a dud.

Read the rest of this entry »

Vytorin No. 3 on list of Top 10 medical stories of 2008

Vytorin has come in at the No. 3 spot on a list of the Top 10 Medical Stories of 2008 – and not in a good way. Dr. Kate Scannell, columnist for the Contra Costa Times, which serves the California Bay Area, listed the drug under the header “statin madness.”

Dr. Scannell said the drug made her list as a result of two studies that revealed , which is a combination of simvastatin (Zocor) and ezetimibe (), did not reduce artery-clogging plaque buildup, although tests showed it reduced “bad” levels.

Read the rest of this entry »